As manager of Pew's drug safety project, Cosel works on federal initiatives to ensure the safety and oversight of the U.S. pharmaceutical supply chain. Prior to joining Pew, Cosel worked on issues of pharmaceutical safety and appropriate prescribing for national advocacy Organization Community Catalyst, and in grassroots development and capacity-building with the Fund for Public Interest Research in Cambridge, Massachusetts.
Cosel received her M.Sc. in human rights from the London School of Economics and a BA from Yale University.
Recent WorkView All
Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a Centers for Disease Control and Prevention report, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die.1 Doctors routinely encounter patients with infections that do not respond to available treatment, and when new... Read More
As of September 2014, there are at least 38 new antibiotics with the potential to treat serious bacterial infections in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients. Read More
The President’s Council of Advisors on Science and Technology (PCAST) released a report to the president Sept. 18 recommending steps the federal government can take to combat antibiotic resistance. Read More